Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Allogeneic stem cell transplantation is an increasingly important treatment option in the management of adult acute myeloid leukemia (AML). The major causes of treatment failure remain disease relapse and treatment toxicity. In this review, Dr Vyas presents an overview of important recent data defining molecular factors associated with treatment failure in AML. He also identifies the emerging importance of leukemia stem cell biology in determining both response to therapy and relapse risk in AML. Dr Appelbaum discusses advances in the design and delivery of both myeloablative and reduced-intensity conditioning regimens, highlighting novel strategies with the potential to improve outcome. Dr Craddock discusses the development of both novel conditioning regimens and post-transplantation strategies aimed at reducing the risk of disease relapse.

Original publication




Journal article


Biol Blood Marrow Transplant

Publication Date





8 - 15


Acute myeloid leukemia, Conditioning regimen, Disease relapse, Graft-versus-leukemia, Leukemic stem/progenitor cell, Reduced-intensity conditioning, Adult, Chromosome Aberrations, Disease Management, Drug Resistance, Neoplasm, Graft vs Leukemia Effect, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Myeloablative Agonists, Neoplastic Stem Cells, Recurrence, Survival Analysis, Transplantation Conditioning, Transplantation, Homologous, Treatment Failure